DFFN will be the first Biotech to be sanctioned by the FDA to conduct a trial in the back of ambulances. DFFN is planning a Ph2 study for its TSC molecule to treat Acute Stroke. The global stroke market has a TAM of $36B TSC is also being studied to speed diffusion of drug thru solid tumors. DFFN has programs in Glioblastoma, Pancreatic Cancer & Brain Metastases. Cash runway extends thru H2/19; but, Ph3 study(ies) will require a partnership or significant dilutive financing.